Edition:
United Kingdom

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

34.42USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$34.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,337
52-wk High
$39.67
52-wk Low
$20.27

Summary

Name Age Since Current Position

David Chiswell

63 2016 Chairman of the Board

Ronald Cooper

54 2016 President, Chief Executive Officer, Director

Thomas Shea

56 2016 Chief Financial Officer, Treasurer

Jan Mattsson

52 2016 Chief Operating Officer

Paresh Soni

57 2016 Chief Medical Officer

Michael Gutch

2016 Director

Roger Jeffs

56 2017 Director

Anne Klibanski

2018 Director

Stephanie Okey

2018 Director

Davey Scoon

71 2012 Director

Brian Pereira

58 2013 Independent Director

Biographies

Name Description

David Chiswell

Ronald Cooper

Mr. Ronald Harold Wilfred Cooper serves as President, Chief Executive Officer, Director of the Company. He has served as Albireo’s President and Chief Executive Officer since July 2015, and has served as a member of the board of directors of Albireo since September 2015. Prior to joining Albireo, Mr. Cooper worked for over 25 years in successive leadership roles at Bristol-Myers Squibb Company, a global biopharmaceutical company. Most recently, at Bristol-Myers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015; President, Northern and Central Europe from April 2009 until April 2010; and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. Previously, Mr. Cooper held multiple senior roles in the U.S. and other countries. Mr. Cooper has served on the board of directors of Genocea Biosciences, Inc., a publicly traded biopharmaceutical company, since June 2016. Mr. Cooper earned his Bachelor’s degree in Chemistry and Business Administration from St. Francis Xavier University in Canada. Mr. Cooper’s qualifications to serve on the Company’s board of directors include his extensive executive leadership and experience in the life sciences industry and his knowledge of the Company’s business as its President and Chief Executive Officer.

Thomas Shea

Mr. Thomas A. Shea is Chief Financial Officer, Treasurer of the company since July 2016. Prior to joining Albireo, Mr. Shea served as Senior Vice President, Chief Financial Officer and Treasurer of EPIRUS Biopharmaceuticals, Inc. from June 2013 to June 2016. He was formerly the Chief Financial Officer of Euthymics Bioscience, Inc., Neurovance, Inc. and EBI Life Sciences, Inc., three affiliated companies developing neurological and pain drug candidates, from 2011 to June 2013. Previously, Mr. Shea was the Chief Financial Officer of Tolerx, Inc., an autoimmune company, for six years, from 2005 to 2011, and Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.) for 10 years. At Cubist, Mr. Shea was a part of the leadership team that transitioned the company from a private to a public company. In July 2016, EPIRUS filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Shea currently serves on the board of directors of Compliance Management Group, a private company.

Jan Mattsson

Dr. Jan P. Mattsson, Ph.D., serves as Chief Operating Officer of the Company. He has served as Chief Operating Officer of Albireo since February 2010. Dr. Mattsson is a co-founder of Albireo and served as the Vice President of Operations from February 2008 to February 2010. He has served as Chief Operating Officer of Albireo AB since February 2010, and Managing Director since March 2008. He has also served as Managing Director of Elobix AB since November 2013. He has served as a director of Albireo AB since May 2008 and Elobix AB since November 2013. He served as a director of Albireo from February 2008 to April 2015. Prior to co-founding Albireo, Dr. Mattsson served as Associate Director at AstraZeneca. Dr. Mattsson holds a Bachelor’s degree in Chemistry and a Ph.D. in Biochemistry from University of Gothenburg.

Paresh Soni

Dr. Paresh N. Soni, M.D., Ph.D., is Chief Medical Officer since September 2016. Prior to joining Albireo, Dr. Soni served as Vice President, Global Medical Sciences at Alexion Pharmaceuticals, Inc., a global rare disease biopharma company, from August 2015 to July 2016, and previously served as Vice President, Alexion Research from June 2014 to July 2015. From August 2013 to June 2014, Dr. Soni provided consulting services in the pharmaceuticals industry. Prior to that, Dr. Soni served as Senior Vice President, Head of Development at Amarin Corporation PLC from September 2008 to August 2013, where he played a key role in the development and regulatory approval of Vascepa® for elevated triglycerides. Dr. Soni began his pharmaceutical career at Pfizer Inc., holding various positions of increasing responsibility. Dr. Soni is an internist and gastroenterologist, and he completed his medical training at the University of Natal in South Africa and a research fellowship at the Division of Hepatology, Royal Free Hospital School of Medicine, London.

Michael Gutch

Roger Jeffs

Dr. Roger Jeffs, Ph.D., serves as Director of the Company. Currently, Dr. Jeffs serves as a Senior Advisor to United Therapeutics Corporation, a biotechnology company focused in rare diseases, where he worked for 18 years, including as President and co-Chief Executive Officer. Dr. Jeffs helped guide United Therapeutics' initial public offering, managed its commercial and business development efforts, and oversaw clinical development and regulatory approval of several new drugs. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments, an investment firm focused on in-licensing and development of early-stage biotechnology assets. Previously, he served as the worldwide clinical leader of the Infectious Disease Program at Amgen Inc. and as a member of the clinical research team at Burroughs Wellcome & Company. In addition to Albireo, Dr. Jeffs is a member on the boards of directors of the public pharmaceutical companies Axsome Therapeutics, Dova Pharmaceuticals and Sangamo Therapeutics. He holds a B.A. in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.

Anne Klibanski

Dr. Anne Klibanski is Director of the Company. Dr. Klibanski is a recognized expert in the field of translational research, with a focus in rare diseases. She currently serves as the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School, as Chief Academic Officer (CAO) for Partners HealthCare and as Academic Dean for Partners HealthCare at Harvard Medical School. In her role as CAO, Dr. Klibanski oversees academic programs in research and education throughout the Partners HealthCare system. Dr. Klibanski also directs the Neuroendocrine Center at Massachusetts General Hospital, where she is a practicing clinician and serves on the General Executive Committee. In addition, Dr. Klibanski is a member of the Scientific Advisory Board for Crinetics Pharmaceuticals and serves on the board of directors for Partners International. Dr. Klibanski received a B.A. from Barnard College and an M.D. from New York University School of Medicine.

Stephanie Okey

Ms. Stephanie Okey is Director of the Company. Ms. Okey brings more than 25 years of experience in the biopharmaceutical industry to Albireo's board of directors. Most recently, she served as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases, at Sanofi Genzyme. Prior to Sanofi Genzyme, Ms. Okey served in roles of increasing leadership at Genentech and Bristol-Myers Squibb. She has extensive experience in the commercialization of drug therapies, including nine rare disease therapeutics and four large-market drug therapies, with a specific focus on bringing therapeutic agents to health care providers, patients and stakeholders in a patient-centric business model. Ms. Okey holds a B.S. from Ohio State University and an M.S. from Wright State University.

Davey Scoon

Mr. Davey S. Scoon is Director of Biodel Inc. Mr. Scoon’s business career has included senior executive positions in Finance and Administration across a range of industries including asset management, insurance, retailing and consumer products. His board leadership positions include board chair and audit chair positions in industries including mutual funds, health insurance and life sciences. Mr. Scoon is currently the Chair of the board of trustees for Allianz Global Investors, a board member and Audit Chair of AMAG Pharmaceuticals, Inc., and a board member of Orthofix International N.V. Previously he served as the Chairman of the audit committees of NitroMed, Inc., CardioKine, Inc. and Orthofix International N.V., and as the non-executive Chairman of Tufts Health Plan. In addition to his board work, Mr. Scoon is an adjunct professor teaching accounting at the University of Wisconsin-Madison. Mr. Scoon is an audit committee financial expert having been a Chief Financial Officer in the manufacturing, financial services and retailing industries. He has an extensive background in risk management, has operated successfully in strictly regulated industries, has been involved in M&A activities throughout his career and has a thorough working knowledge of Sarbanes Oxley. Mr. Scoon’s previous corporate experience includes Chief Administrative and Financial Officer of Tom’s of Maine, Inc., Chief Administrative and Financial Officer of Sunlife Financial U.S., Executive Vice President and Chief Operating Officer of Liberty Funds Group of Boston (formerly Colonial Management) and Certified Public Accountant with Price Waterhouse & Company. Mr. Scoon earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin. We believe Mr. Scoon’s qualifications to serve on our board of directors include his many years serving as a senior executive with public companies, his expertise with finance and administration, and his extensive experience serving on boards of directors.

Brian Pereira

Dr. Brian J.G. Pereira, M.D., is an Independent Director of the Board of Biodel Inc. He is currently President and CEO of Visterra Inc., a biotechnology company that uses its Atomic Interaction Network analysis technology to identify unique disease targets and design effective therapeutics. Dr. Pereira previously served as President and CEO of AMAG Pharmaceuticals, Inc., a biopharmaceutical company, from 2006 to 2011 and President from 2005 to 2006. Prior to AMAG Pharmaceuticals, Dr. Pereira was President and Chief Executive Officer of the New England Health Care Foundation, a physician’s group at Tufts-New England Medical Center from 2001 to 2005, and he held various other positions at Tufts-New England Medical Center from 1993 to 2001. From 2002 to 2004, Dr. Pereira served as President of the National Kidney Foundation, and has served on the editorial board of twelve scientific journals. Dr. Pereira is a nationally recognized expert on kidney disease and nephrology, is the Editor of the widely read textbook “Chronic Kidney Disease, Dialysis and Transplantation”, and has over 200 scientific papers to his credit. He is Adjunct Professor of Medicine at Tufts University School of Medicine and at the Sackler School of Biomedical Sciences of Tufts University. He currently serves on the Board of Directors of NephroPLus, Ltd, a dialysis services company, the American India Foundation, and Youth That Care, Inc. Dr. Pereira is a graduate of St. John’s Medical College, Bangalore, India and has an MBA from the Kellogg Business School, Northwestern University.